DNA methylation-based biomarkers of age acceleration and all-cause death, myocardial infarction, stroke, and cancer in two cohorts: The NAS, and KORA F4
Background: DNA methylation (DNAm) may play a role in age-related outcomes. It is not yet known which DNAm-based biomarkers of age acceleration (BoAA) has the strongest association with age-related endpoints. Methods: We collected the blood samples from two independent cohorts: the Normative Ageing...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-01-01
|
| Series: | EBioMedicine |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2352396420305272 |
| _version_ | 1818393111789830144 |
|---|---|
| author | Cuicui Wang Wenli Ni Yueli Yao Allan Just Jonathan Heiss Yaguang Wei Xu Gao Brent A. Coull Anna Kosheleva Andrea A. Baccarelli Annette Peters Joel D. Schwartz |
| author_facet | Cuicui Wang Wenli Ni Yueli Yao Allan Just Jonathan Heiss Yaguang Wei Xu Gao Brent A. Coull Anna Kosheleva Andrea A. Baccarelli Annette Peters Joel D. Schwartz |
| author_sort | Cuicui Wang |
| collection | DOAJ |
| description | Background: DNA methylation (DNAm) may play a role in age-related outcomes. It is not yet known which DNAm-based biomarkers of age acceleration (BoAA) has the strongest association with age-related endpoints. Methods: We collected the blood samples from two independent cohorts: the Normative Ageing Study, and the Cooperative Health Research in the Region of Augsburg cohort. We measured epigenome-wide DNAm level, and generated five DNAm BoAA at baseline. We used Cox proportional hazards model to analyze the relationships between BoAA and all-cause death. We applied the Fine and Gray competing risk model to estimate the risk of BoAA on myocardial infarction (MI), stroke, and cancer, accounting for death of other reasons as the competing risks. We used random-effects meta-analyses to pool the individual results, with adjustment for multiple testing. Findings: The mean chronological ages in the two cohorts were 74, and 61, respectively. Baseline GrimAgeAccel, and DNAm-related mortality risk score (DNAmRS) both had strong associations with all-cause death, MI, and stroke, independent from chronological age. For example, a one standard deviation (SD) increment in GrimAgeAccel was significantly associated with increased risk of all-cause death [hazard ratio (HR): 2.01; 95% confidence interval (CI), 1.15, 3.50], higher risk of MI (HR: 1.44; 95% CI, 1.16, 1.79), and elevated risk of stroke (HR: 1.42; 95% CI, 1.06, 1.91). There were no associations between any BoAA and cancer. Interpretation: From the public health perspective, GrimAgeAccel is the most useful tool for identifying at-risk elderly, and evaluating the efficacy of anti-aging interventions. Funding: National Institute of Environmental Health Sciences of U.S., Harvard Chan-NIEHS Center for Environmental Health, German Federal Ministry of Education and Research, and the State of Bavaria in Germany. |
| first_indexed | 2024-12-14T05:40:07Z |
| format | Article |
| id | doaj.art-991018e7294642fa98fae26bb6a71742 |
| institution | Directory Open Access Journal |
| issn | 2352-3964 |
| language | English |
| last_indexed | 2024-12-14T05:40:07Z |
| publishDate | 2021-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | EBioMedicine |
| spelling | doaj.art-991018e7294642fa98fae26bb6a717422022-12-21T23:15:03ZengElsevierEBioMedicine2352-39642021-01-0163103151DNA methylation-based biomarkers of age acceleration and all-cause death, myocardial infarction, stroke, and cancer in two cohorts: The NAS, and KORA F4Cuicui Wang0Wenli Ni1Yueli Yao2Allan Just3Jonathan Heiss4Yaguang Wei5Xu Gao6Brent A. Coull7Anna Kosheleva8Andrea A. Baccarelli9Annette Peters10Joel D. Schwartz11Department of Environmental Health, Harvard T.H. Chan School of Public Health, 401 Park Drive, West of Landmark Center, Boston, MA 02215, United States; Corresponding author.Institute of Epidemiology, Helmholtz Zentrum München, Neuherberg, GermanyInstitute of Epidemiology, Helmholtz Zentrum München, Neuherberg, GermanyDepartment of Environmental Medicine, and Public Health, Icahn School of Medicine at Mount Sinai, New York, NY, United StatesDepartment of Environmental Medicine, and Public Health, Icahn School of Medicine at Mount Sinai, New York, NY, United StatesDepartment of Environmental Health, Harvard T.H. Chan School of Public Health, 401 Park Drive, West of Landmark Center, Boston, MA 02215, United StatesDepartment of Environmental Health Sciences, Mailman School of Public Health, Columbia University, New York, NY, United StatesDepartment of Environmental Health, Harvard T.H. Chan School of Public Health, 401 Park Drive, West of Landmark Center, Boston, MA 02215, United States; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA 02115, United StatesDepartment of Environmental Health, Harvard T.H. Chan School of Public Health, 401 Park Drive, West of Landmark Center, Boston, MA 02215, United StatesDepartment of Environmental Health Sciences, Mailman School of Public Health, Columbia University, New York, NY, United StatesInstitute of Epidemiology, Helmholtz Zentrum München, Neuherberg, Germany; Institute of Medical Information Science, Biometry, and Epidemiology, Ludwig Maximilians University, Munich, GermanyDepartment of Environmental Health, Harvard T.H. Chan School of Public Health, 401 Park Drive, West of Landmark Center, Boston, MA 02215, United StatesBackground: DNA methylation (DNAm) may play a role in age-related outcomes. It is not yet known which DNAm-based biomarkers of age acceleration (BoAA) has the strongest association with age-related endpoints. Methods: We collected the blood samples from two independent cohorts: the Normative Ageing Study, and the Cooperative Health Research in the Region of Augsburg cohort. We measured epigenome-wide DNAm level, and generated five DNAm BoAA at baseline. We used Cox proportional hazards model to analyze the relationships between BoAA and all-cause death. We applied the Fine and Gray competing risk model to estimate the risk of BoAA on myocardial infarction (MI), stroke, and cancer, accounting for death of other reasons as the competing risks. We used random-effects meta-analyses to pool the individual results, with adjustment for multiple testing. Findings: The mean chronological ages in the two cohorts were 74, and 61, respectively. Baseline GrimAgeAccel, and DNAm-related mortality risk score (DNAmRS) both had strong associations with all-cause death, MI, and stroke, independent from chronological age. For example, a one standard deviation (SD) increment in GrimAgeAccel was significantly associated with increased risk of all-cause death [hazard ratio (HR): 2.01; 95% confidence interval (CI), 1.15, 3.50], higher risk of MI (HR: 1.44; 95% CI, 1.16, 1.79), and elevated risk of stroke (HR: 1.42; 95% CI, 1.06, 1.91). There were no associations between any BoAA and cancer. Interpretation: From the public health perspective, GrimAgeAccel is the most useful tool for identifying at-risk elderly, and evaluating the efficacy of anti-aging interventions. Funding: National Institute of Environmental Health Sciences of U.S., Harvard Chan-NIEHS Center for Environmental Health, German Federal Ministry of Education and Research, and the State of Bavaria in Germany.http://www.sciencedirect.com/science/article/pii/S2352396420305272DNA methylation based biomarkers of age accelerationAll-cause deathMyocardial infarctionStrokeCancerCompeting risk |
| spellingShingle | Cuicui Wang Wenli Ni Yueli Yao Allan Just Jonathan Heiss Yaguang Wei Xu Gao Brent A. Coull Anna Kosheleva Andrea A. Baccarelli Annette Peters Joel D. Schwartz DNA methylation-based biomarkers of age acceleration and all-cause death, myocardial infarction, stroke, and cancer in two cohorts: The NAS, and KORA F4 EBioMedicine DNA methylation based biomarkers of age acceleration All-cause death Myocardial infarction Stroke Cancer Competing risk |
| title | DNA methylation-based biomarkers of age acceleration and all-cause death, myocardial infarction, stroke, and cancer in two cohorts: The NAS, and KORA F4 |
| title_full | DNA methylation-based biomarkers of age acceleration and all-cause death, myocardial infarction, stroke, and cancer in two cohorts: The NAS, and KORA F4 |
| title_fullStr | DNA methylation-based biomarkers of age acceleration and all-cause death, myocardial infarction, stroke, and cancer in two cohorts: The NAS, and KORA F4 |
| title_full_unstemmed | DNA methylation-based biomarkers of age acceleration and all-cause death, myocardial infarction, stroke, and cancer in two cohorts: The NAS, and KORA F4 |
| title_short | DNA methylation-based biomarkers of age acceleration and all-cause death, myocardial infarction, stroke, and cancer in two cohorts: The NAS, and KORA F4 |
| title_sort | dna methylation based biomarkers of age acceleration and all cause death myocardial infarction stroke and cancer in two cohorts the nas and kora f4 |
| topic | DNA methylation based biomarkers of age acceleration All-cause death Myocardial infarction Stroke Cancer Competing risk |
| url | http://www.sciencedirect.com/science/article/pii/S2352396420305272 |
| work_keys_str_mv | AT cuicuiwang dnamethylationbasedbiomarkersofageaccelerationandallcausedeathmyocardialinfarctionstrokeandcancerintwocohortsthenasandkoraf4 AT wenlini dnamethylationbasedbiomarkersofageaccelerationandallcausedeathmyocardialinfarctionstrokeandcancerintwocohortsthenasandkoraf4 AT yueliyao dnamethylationbasedbiomarkersofageaccelerationandallcausedeathmyocardialinfarctionstrokeandcancerintwocohortsthenasandkoraf4 AT allanjust dnamethylationbasedbiomarkersofageaccelerationandallcausedeathmyocardialinfarctionstrokeandcancerintwocohortsthenasandkoraf4 AT jonathanheiss dnamethylationbasedbiomarkersofageaccelerationandallcausedeathmyocardialinfarctionstrokeandcancerintwocohortsthenasandkoraf4 AT yaguangwei dnamethylationbasedbiomarkersofageaccelerationandallcausedeathmyocardialinfarctionstrokeandcancerintwocohortsthenasandkoraf4 AT xugao dnamethylationbasedbiomarkersofageaccelerationandallcausedeathmyocardialinfarctionstrokeandcancerintwocohortsthenasandkoraf4 AT brentacoull dnamethylationbasedbiomarkersofageaccelerationandallcausedeathmyocardialinfarctionstrokeandcancerintwocohortsthenasandkoraf4 AT annakosheleva dnamethylationbasedbiomarkersofageaccelerationandallcausedeathmyocardialinfarctionstrokeandcancerintwocohortsthenasandkoraf4 AT andreaabaccarelli dnamethylationbasedbiomarkersofageaccelerationandallcausedeathmyocardialinfarctionstrokeandcancerintwocohortsthenasandkoraf4 AT annettepeters dnamethylationbasedbiomarkersofageaccelerationandallcausedeathmyocardialinfarctionstrokeandcancerintwocohortsthenasandkoraf4 AT joeldschwartz dnamethylationbasedbiomarkersofageaccelerationandallcausedeathmyocardialinfarctionstrokeandcancerintwocohortsthenasandkoraf4 |